Free Trial

Pliant Therapeutics (PLRX) Competitors

Pliant Therapeutics logo
$1.57 -0.08 (-4.85%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$1.59 +0.02 (+1.02%)
As of 10/17/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PLRX vs. LRMR, ACIU, REPL, AARD, LBRX, ALT, DMAC, TNYA, ANNX, and CADL

Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Larimar Therapeutics (LRMR), AC Immune (ACIU), Replimune Group (REPL), Aardvark Therapeutics (AARD), LB Pharmaceuticals (LBRX), Altimmune (ALT), DiaMedica Therapeutics (DMAC), Tenaya Therapeutics (TNYA), Annexon (ANNX), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

Pliant Therapeutics vs. Its Competitors

Pliant Therapeutics (NASDAQ:PLRX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Larimar Therapeutics' return on equity of -62.92% beat Pliant Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pliant TherapeuticsN/A -73.45% -55.66%
Larimar Therapeutics N/A -62.92%-53.98%

97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Larimar Therapeutics had 6 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for Larimar Therapeutics and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.24 beat Larimar Therapeutics' score of 0.23 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pliant Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Larimar Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pliant Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Pliant Therapeutics currently has a consensus target price of $8.19, indicating a potential upside of 421.50%. Larimar Therapeutics has a consensus target price of $16.71, indicating a potential upside of 297.96%. Given Pliant Therapeutics' higher possible upside, equities analysts clearly believe Pliant Therapeutics is more favorable than Larimar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pliant Therapeutics
2 Sell rating(s)
11 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.93
Larimar Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

Larimar Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$1.58M61.00-$210.30M-$3.40-0.46
Larimar TherapeuticsN/AN/A-$80.60M-$1.56-2.69

Summary

Pliant Therapeutics and Larimar Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLRX vs. The Competition

MetricPliant TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$101.29M$3.40B$6.10B$10.50B
Dividend YieldN/A2.29%5.73%4.81%
P/E Ratio-0.4622.4484.5227.09
Price / Sales61.00489.40611.79219.27
Price / CashN/A46.5937.1661.22
Price / Book0.3110.4112.246.52
Net Income-$210.30M-$52.47M$3.32B$276.75M
7 Day Performance6.80%2.32%1.25%2.00%
1 Month Performance5.37%11.14%6.28%2.26%
1 Year Performance-89.67%11.15%59.92%35.58%

Pliant Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLRX
Pliant Therapeutics
3.8329 of 5 stars
$1.57
-4.8%
$8.19
+421.5%
-89.3%$101.29M$1.58M-0.4690
LRMR
Larimar Therapeutics
3.1714 of 5 stars
$4.25
-2.5%
$16.71
+293.3%
-46.5%$360.91MN/A-2.7230
ACIU
AC Immune
2.2558 of 5 stars
$3.47
-2.3%
$10.00
+188.2%
-9.7%$356.46M$31.02M-5.98140Positive News
REPL
Replimune Group
4.3302 of 5 stars
$4.56
+0.7%
$6.50
+42.5%
-60.2%$353.59MN/A-1.41210Analyst Forecast
AARD
Aardvark Therapeutics
3.6879 of 5 stars
$14.63
-10.0%
$31.43
+114.8%
N/A$352.79MN/A0.0018Short Interest ↑
LBRX
LB Pharmaceuticals
N/A$16.07
+4.1%
$30.50
+89.8%
N/A$346.52MN/A0.0016Positive News
Quiet Period Expiration
ALT
Altimmune
2.3222 of 5 stars
$4.00
+2.0%
$17.40
+335.0%
-43.6%$345.97M$20K-3.3950
DMAC
DiaMedica Therapeutics
1.0127 of 5 stars
$7.06
+6.3%
$12.33
+74.7%
+53.4%$343.21MN/A-10.2320
TNYA
Tenaya Therapeutics
3.2405 of 5 stars
$1.98
-5.7%
$6.25
+215.7%
-15.8%$342.25MN/A-2.06110High Trading Volume
ANNX
Annexon
1.4668 of 5 stars
$3.01
-2.9%
$12.50
+315.3%
-58.7%$340.65MN/A-2.3360
CADL
Candel Therapeutics
2.5686 of 5 stars
$6.47
+4.5%
$20.00
+209.1%
-9.2%$339.80M$120K-9.3860

Related Companies and Tools


This page (NASDAQ:PLRX) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners